Login to Your Account

Aeterna Zentaris seeks second go with FDA on Macrilen

By Marie Powers
News Editor

Monday, February 13, 2017

Aeterna Zentaris Inc. completed a full review of data from its confirmatory phase III trial of oral Macrilen for use as a growth hormone stimulation test to assess growth hormone deficiency in adults and concluded the data were sufficient to make a second run at registration with the FDA.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription